EP1541574A4 - TRIAZASPIRO DERIVATIVES 5.5 | UNDECANS AND DRUGS CONTAINING THEM AS AN ACTIVE INGREDIENT - Google Patents

TRIAZASPIRO DERIVATIVES 5.5 | UNDECANS AND DRUGS CONTAINING THEM AS AN ACTIVE INGREDIENT

Info

Publication number
EP1541574A4
EP1541574A4 EP03753933A EP03753933A EP1541574A4 EP 1541574 A4 EP1541574 A4 EP 1541574A4 EP 03753933 A EP03753933 A EP 03753933A EP 03753933 A EP03753933 A EP 03753933A EP 1541574 A4 EP1541574 A4 EP 1541574A4
Authority
EP
European Patent Office
Prior art keywords
allergic
diseases
general formula
immune
comprisi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03753933A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1541574A1 (en
Inventor
Yoshikazu Takaoka
Rena Nishizawa
Shiro Shibayama
Kenji Sagawa
Masayoshi Matsuo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ono Pharmaceutical Co Ltd
Original Assignee
Ono Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co Ltd filed Critical Ono Pharmaceutical Co Ltd
Publication of EP1541574A1 publication Critical patent/EP1541574A1/en
Publication of EP1541574A4 publication Critical patent/EP1541574A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
EP03753933A 2002-09-18 2003-09-17 TRIAZASPIRO DERIVATIVES 5.5 | UNDECANS AND DRUGS CONTAINING THEM AS AN ACTIVE INGREDIENT Withdrawn EP1541574A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2002270849 2002-09-18
JP2002270849 2002-09-18
PCT/JP2003/011834 WO2004026873A1 (ja) 2002-09-18 2003-09-17 トリアザスピロ[５.５]ウンデカン誘導体およびそれらを有効成分とする薬剤

Publications (2)

Publication Number Publication Date
EP1541574A1 EP1541574A1 (en) 2005-06-15
EP1541574A4 true EP1541574A4 (en) 2007-06-20

Family

ID=32024865

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03753933A Withdrawn EP1541574A4 (en) 2002-09-18 2003-09-17 TRIAZASPIRO DERIVATIVES 5.5 | UNDECANS AND DRUGS CONTAINING THEM AS AN ACTIVE INGREDIENT

Country Status (15)

Country Link
US (1) US20050267114A1 (ja)
EP (1) EP1541574A4 (ja)
JP (1) JPWO2004026873A1 (ja)
KR (1) KR20050057408A (ja)
CN (1) CN1688577A (ja)
AU (1) AU2003272879A1 (ja)
BR (1) BR0314304A (ja)
CA (1) CA2497903A1 (ja)
MX (1) MXPA05002771A (ja)
NO (1) NO20051379L (ja)
PL (1) PL376154A1 (ja)
RU (1) RU2005111225A (ja)
TW (1) TW200413372A (ja)
WO (1) WO2004026873A1 (ja)
ZA (1) ZA200502222B (ja)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003271057A1 (en) * 2002-09-18 2004-04-08 Ono Pharmaceutical Co., Ltd. Novel crystals of triazaspiro(5.5)undecane derivative
CA2517888C (en) * 2003-03-14 2012-05-01 Ono Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient
EP1621540A4 (en) * 2003-04-21 2008-07-23 Ono Pharmaceutical Co HETEROCYCLIC COMPOUNDS CONTAINING NITROGEN AND USE THEREOF
US7498346B2 (en) * 2003-12-11 2009-03-03 Genzyme Corporation Chemokine receptor binding compounds
TWI400232B (zh) 2004-09-13 2013-07-01 Ono Pharmaceutical Co 含氮雜環衍生物及以該含氮雜環衍生物為有效成分之藥劑
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
CN101163690A (zh) 2005-04-20 2008-04-16 默克公司 苯并噻吩异羟肟酸衍生物
JP2008536924A (ja) 2005-04-20 2008-09-11 メルク エンド カムパニー インコーポレーテッド ベンゾチオフェンヒドロキサミン酸のカーバメート、ウレア、アミドおよびスルホンアミド置換誘導体
WO2006115845A1 (en) 2005-04-20 2006-11-02 Merck & Co., Inc. Benzothiophene derivatives
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US20110052612A1 (en) * 2005-05-31 2011-03-03 Ono Pharmaceutical Co., Ltd. Spiropiperidine compound and medicinal use thereof
AU2006262166A1 (en) 2005-06-24 2007-01-04 Merck Sharp & Dohme Corp. Modified malonate derivatives
EP2532677A1 (en) 2005-10-21 2012-12-12 Novartis AG Human antibodies against il13 and therapeutic uses
AR057579A1 (es) 2005-11-23 2007-12-05 Merck & Co Inc Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac)
GB0526244D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
AU2007221207A1 (en) 2006-02-28 2007-09-07 Merck Sharp & Dohme Corp. Inhibitors of histone deacetylase
CA2644368A1 (en) * 2006-03-10 2007-09-20 Ono Pharmaceutical Co., Ltd. Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient
PL2322525T3 (pl) 2006-04-21 2014-03-31 Novartis Ag Pochodne puryny do zastosowania jako agoniści receptora adenozyny A<sub>2A</sub>
AU2007243519A1 (en) 2006-04-26 2007-11-08 Merck Sharp & Dohme Corp. Disubstituted aniline compounds
JP2009537529A (ja) 2006-05-18 2009-10-29 メルク エンド カムパニー インコーポレーテッド アリール縮合スピロ環化合物
US7981874B2 (en) 2006-07-20 2011-07-19 Merck Sharp & Dohme Corp. Phosphorus derivatives as histone deacetylase inhibitors
AU2007297285A1 (en) * 2006-09-08 2008-03-20 Pfizer Products Inc. Diaryl ether derivatives and uses thereof
BRPI0717564A2 (pt) 2006-09-29 2013-10-22 Novartis Ag Pirazolopirimidinas como inibidores de pi3k lipídeo cinase
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
RS51644B (en) 2007-01-10 2011-10-31 Irm Llc. UNITS AND PREPARATIONS AS CHANNEL INHIBITORS ACTIVATING PROSTHESES
WO2008090944A1 (ja) * 2007-01-25 2008-07-31 Takeda Pharmaceutical Company Limited スピロ環化合物
PL2155721T3 (pl) 2007-05-07 2011-07-29 Novartis Ag Związki organiczne
AU2008271170A1 (en) 2007-06-27 2009-01-08 Merck Sharp & Dohme Corp. Pyridyl and pyrimidinyl derivatives as histone deacetylase inhibitors
EP3103791B1 (en) 2007-06-27 2018-01-31 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
PT2444120T (pt) 2007-12-10 2018-01-03 Novartis Ag Análogos da amilorida espirocíclicos como bloqueadores de enac
AU2009256645A1 (en) 2008-06-10 2009-12-17 Novartis Ag Pyrazine derivatives as epithelial sodium channel blockers
WO2010009196A1 (en) * 2008-07-15 2010-01-21 Temple University Of The Commonwealth System Of Higher Education Synthesis of bis-peptides oligomers comprising at least one n-substituted diketopiperazine as structural moiety
ES2396023T3 (es) 2009-01-29 2013-02-18 Novartis Ag Bencimidazoles sustituidos para el tratamiento de astrocitomas
WO2010098866A1 (en) 2009-02-27 2010-09-02 Supergen, Inc. Cyclopentathiophene/cyclohexathiophene dna methyltransferase inhibitors
AU2010256360A1 (en) 2009-06-05 2012-01-12 Astrazeneca Ab Aminopyrrolidinone derivatives and uses thereof
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
JP5781510B2 (ja) 2009-08-12 2015-09-24 ノバルティス アーゲー ヘテロ環式ヒドラゾン化合物および癌および炎症の処置のためのそれらの使用
JP5819831B2 (ja) 2009-08-17 2015-11-24 インテリカイン， エルエルシー 複素環式化合物およびそれらの使用
WO2011020861A1 (en) 2009-08-20 2011-02-24 Novartis Ag Heterocyclic oxime compounds
EP2813227A1 (en) 2009-10-22 2014-12-17 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
MX342288B (es) 2010-04-22 2016-09-23 Vertex Pharma Proceso para producir compuestos de cicloalquilcarboxamido-indol.
WO2011143444A2 (en) * 2010-05-14 2011-11-17 President And Fellows Of Harvard College Diphenylbutypiperidine autophagy inducers
SG186989A1 (en) 2010-07-14 2013-02-28 Novartis Ag Ip receptor agonist heterocyclic compounds
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
JP2014505088A (ja) 2011-02-10 2014-02-27 ノバルティス アーゲー Ｃ−ＭＥＴチロシンキナーゼ阻害剤としての［１，２，４］トリアゾロ［４，３−ｂ］ピリダジン化合物
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
JP5957526B2 (ja) 2011-09-15 2016-07-27 ノバルティス アーゲー チロシンキナーゼとしての６−置換３−（キノリン−６−イルチオ）−［１，２，４］トリアゾロ［４，３−ａ］ピラジン
ES2558457T3 (es) 2011-09-16 2016-02-04 Novartis Ag Compuestos heterocíclicos para el tratamiento de fibrosis quística
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
EP2755652B1 (en) 2011-09-16 2021-06-02 Novartis AG N-substituted heterocyclyl carboxamides
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
EP2793893A4 (en) 2011-11-23 2015-07-08 Intellikine Llc IMPROVED TREATMENT REGIMES USING MTOR INHIBITORS
EP2802585A1 (en) 2012-01-13 2014-11-19 Novartis AG Fused piperidines as ip receptor agonists for the treatment of pah and related disorders
TW201335160A (zh) 2012-01-13 2013-09-01 Novartis Ag Ｉｐ受體激動劑之雜環化合物
US20150005311A1 (en) 2012-01-13 2015-01-01 Novartis Ag IP receptor agonist heterocyclic compounds
US20140357641A1 (en) 2012-01-13 2014-12-04 Novartis Ag IP receptor agonist heterocyclic compounds
WO2013105066A1 (en) 2012-01-13 2013-07-18 Novartis Ag Salts of an ip receptor agonist
EP2802581A1 (en) 2012-01-13 2014-11-19 Novartis AG 7,8- dihydropyrido [3, 4 - b]pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
RU2502738C2 (ru) * 2012-02-07 2013-12-27 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Пермский государственный национальный исследовательский университет" 1,6'-ДИАРИЛ-3-АРОИЛ-4-ГИДРОКСИ-1',3'-ДИМЕТИЛСПИРО[ПИРРОЛ-2,5'-ПИРРОЛО[2,3-d]ПИРИМИДИН]-2',4',5(1Н,1'Н,3'Н)-ТРИОНЫ И СПОСОБ ИХ ПОЛУЧЕНИЯ
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
EP3964513A1 (en) 2012-04-03 2022-03-09 Novartis AG Combination products with tyrosine kinase inhibitors and their use
JP2016507582A (ja) 2013-02-13 2016-03-10 ノバルティス アーゲー Ｉｐ受容体アゴニスト複素環式化合物
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
CN105246482A (zh) 2013-03-15 2016-01-13 因特利凯有限责任公司 激酶抑制剂的组合及其用途
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
ES2957761T3 (es) 2014-04-15 2024-01-25 Vertex Pharma Composiciones farmacéuticas para el tratamiento de enfermedades mediadas por el regulador de la conductancia transmembrana de fibrosis quística
KR20160141856A (ko) 2014-04-24 2016-12-09 노파르티스 아게 포스파티딜이노시톨 3-키나제 억제제로서의 피라진 유도체
PT3134396T (pt) 2014-04-24 2019-12-16 Novartis Ag Derivados de amino piridina como inibidores da fosfatidilinositol 3-quinase
CN106458979B (zh) 2014-04-24 2020-03-27 诺华股份有限公司 作为磷脂酰肌醇3-激酶抑制剂的氨基吡嗪衍生物
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
US10195208B2 (en) 2014-07-31 2019-02-05 Novartis Ag Combination therapy
WO2016140501A1 (en) * 2015-03-04 2016-09-09 Kainos Medicine, Inc. Pyridine n-oxide for enhancer of zeste homolog 2 inhibitors
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
EP3759109B1 (en) 2018-02-26 2023-08-30 Gilead Sciences, Inc. Substituted pyrrolizine compounds as hbv replication inhibitors
WO2020246487A1 (ja) * 2019-06-04 2020-12-10 第一三共株式会社 ジスピロジケトピペラジン構造を有する化合物
WO2020250116A1 (en) 2019-06-10 2020-12-17 Novartis Ag Pyridine and pyrazine derivative for the treatment of cf, copd, and bronchiectasis
JOP20220044A1 (ar) 2019-08-28 2023-01-30 Novartis Ag مشتقات 1، 3- فينيل أريل غير متجانسة بها استبدال واستخدامها في معالجة مرض
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003104233A1 (en) * 2002-06-07 2003-12-18 Altana Pharma Ag 4,5-dihydro-imidazo (4,5,1-ij) quinolin-6-ones derivatives and their use as poly (adp-ribosyl) transferase (parp) inhibitors
WO2004024683A2 (en) * 2002-09-13 2004-03-25 University Of Maryland Biotechnology COMPOSITIONS FOR INDUCING INCREASED LEVELS OF β-CHEMOKINES AND METHODS OF USE THEREFOR
WO2004033663A2 (en) * 2002-10-11 2004-04-22 University Of Maryland Biotechnology Institute Off. Of Research Admin./ Tech. Dev. Carbohydrate-based synthetic vaccines for hiv
WO2005001027A2 (en) * 2003-05-16 2005-01-06 University Of Maryland Biotechnology Institute Compositions for down-regulation of ccr5 expression and methods of use therefor
WO2005007656A1 (en) * 2003-07-18 2005-01-27 Virochem Pharma Inc. Spiro compounds and methods for the modulation of chemokine receptor activity
WO2005016226A2 (en) * 2003-08-14 2005-02-24 Hadasit Medical Research Services & Development Ltd. Pharmaceutical compositions comprising ccr5 antagonists
EP1541573A1 (en) * 2002-09-18 2005-06-15 Ono Pharmaceutical Co., Ltd. Novel crystals of triazaspiro 5.5 undecane derivative
EP1553098A1 (en) * 2002-10-18 2005-07-13 Ono Pharmaceutical Co., Ltd. Spiroheterocyclic derivative compounds and drugs comprising the compounds as the active ingredient
EP1619193A1 (en) * 2003-04-18 2006-01-25 Ono Pharmaceutical Co., Ltd. Spiropiperidine compound and medicinal use thereof
EP1623721A1 (en) * 2003-05-06 2006-02-08 Ono Pharmaceutical Co., Ltd. Effector cell function inhibitor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001508798A (ja) * 1997-01-21 2001-07-03 メルク エンド カンパニー インコーポレーテッド ケモカインレセプター活性のモジュレーターとしての３，３−二置換ピペリジン類
US6288083B1 (en) * 1998-09-04 2001-09-11 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
CN1246321C (zh) * 1999-12-03 2006-03-22 小野药品工业株式会社 三氮杂螺[5,5]十一烷衍生物和含其作为活性成分的药物组合物
EP1619194A3 (en) * 2001-03-19 2006-06-07 Ono Pharmaceutical Co., Ltd. Triazaspiro¬5.5|undecane derivatives and pharmaceutical composition comprising the same as active ingredient
NZ528270A (en) * 2001-03-19 2005-10-28 Ono Pharmaceutical Co Drugs containing triazaspiro[5.5]undecane derivatives as the active ingredient
JP2002348288A (ja) * 2001-05-28 2002-12-04 Ono Pharmaceut Co Ltd スピロ複素環誘導体およびそれらを有効成分とする薬剤
MXPA04003816A (es) * 2001-10-23 2004-07-30 Ono Pharmaceutical Co Medicamento que comprende combinacion de derivado de triazaespiro[5.5]undecano con inhibidor de isozima 3a4 de citocromo p450 y/o inhibidor de p-glicoproteina.

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003104233A1 (en) * 2002-06-07 2003-12-18 Altana Pharma Ag 4,5-dihydro-imidazo (4,5,1-ij) quinolin-6-ones derivatives and their use as poly (adp-ribosyl) transferase (parp) inhibitors
WO2004024683A2 (en) * 2002-09-13 2004-03-25 University Of Maryland Biotechnology COMPOSITIONS FOR INDUCING INCREASED LEVELS OF β-CHEMOKINES AND METHODS OF USE THEREFOR
EP1541573A1 (en) * 2002-09-18 2005-06-15 Ono Pharmaceutical Co., Ltd. Novel crystals of triazaspiro 5.5 undecane derivative
WO2004033663A2 (en) * 2002-10-11 2004-04-22 University Of Maryland Biotechnology Institute Off. Of Research Admin./ Tech. Dev. Carbohydrate-based synthetic vaccines for hiv
EP1553098A1 (en) * 2002-10-18 2005-07-13 Ono Pharmaceutical Co., Ltd. Spiroheterocyclic derivative compounds and drugs comprising the compounds as the active ingredient
EP1619193A1 (en) * 2003-04-18 2006-01-25 Ono Pharmaceutical Co., Ltd. Spiropiperidine compound and medicinal use thereof
EP1623721A1 (en) * 2003-05-06 2006-02-08 Ono Pharmaceutical Co., Ltd. Effector cell function inhibitor
WO2005001027A2 (en) * 2003-05-16 2005-01-06 University Of Maryland Biotechnology Institute Compositions for down-regulation of ccr5 expression and methods of use therefor
WO2005007656A1 (en) * 2003-07-18 2005-01-27 Virochem Pharma Inc. Spiro compounds and methods for the modulation of chemokine receptor activity
WO2005016226A2 (en) * 2003-08-14 2005-02-24 Hadasit Medical Research Services & Development Ltd. Pharmaceutical compositions comprising ccr5 antagonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2004026873A1 *

Also Published As

Publication number Publication date
MXPA05002771A (es) 2005-06-06
KR20050057408A (ko) 2005-06-16
CA2497903A1 (en) 2004-04-01
AU2003272879A1 (en) 2004-04-08
TW200413372A (en) 2004-08-01
CN1688577A (zh) 2005-10-26
JPWO2004026873A1 (ja) 2006-01-19
NO20051379L (no) 2005-06-17
PL376154A1 (en) 2005-12-27
EP1541574A1 (en) 2005-06-15
US20050267114A1 (en) 2005-12-01
WO2004026873A1 (ja) 2004-04-01
ZA200502222B (en) 2005-12-28
BR0314304A (pt) 2005-07-26
RU2005111225A (ru) 2005-08-27

Similar Documents

Publication Publication Date Title
EP1541574A4 (en) TRIAZASPIRO DERIVATIVES 5.5 | UNDECANS AND DRUGS CONTAINING THEM AS AN ACTIVE INGREDIENT
EP1604981A4 (en) NITROGENIC HETEROCYCLIC DERIVATIVES AND MEDICAMENTS CONTAINING THEM AS AN ACTIVE SUBSTANCE
SG146673A1 (en) Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient
EP3360554B1 (en) Anti-hepatitis b virus agent
CA2371587A1 (en) Piperidine derivatives useful as ccr5 antagonists
EP1661889A4 (en) ANTAGONIST OF THE CHEMOKINE RECEPTOR AND ITS USE FOR MEDICAL PURPOSES
EP1541563A4 (en) ANTAGONIST OF CCR4 AND CORRESPONDING MEDICINAL USE
CA2371583A1 (en) Piperazine derivatives useful as ccr5 antagonists
AU780419C (en) Triazaspiro(5.5)undecane derivatives and drugs containing the same as the active ingredient
CA2285548A1 (en) Nicotinamide derivatives
WO2003035639A1 (fr) Compose de pyrimidine et composition medicinale contenant ledit compose
AP2001002068A0 (en) Substituted 1,8-naphthyridin-4(1H)-ones as phosphodiesterase 4 inhibitors.
CA2021925A1 (en) Pyridopyrimidine derivatives
MX281941B (en) Anthranilamide compounds, process for their production and pesticides containing them
WO2006003500A8 (en) Method for preparing 5-`4-(2-hydroxy-propyl)-3,5-dioxo-4,5-dihydro-3h`1,2,4!triazin-2-yl!-benzamide derivatives by deprotecting the hydroxyl-protected precursers
MXPA05010055A (es) Derivados de 2-fenoxi- y 2-fenil-sulfomamida con actividad antagonista del ccr3, para el tratamiento del asma y otros desordenes inflamatorios o inmunologicos.
NO20034148D0 (no) Triazaspiro[5.5]undekanderivater og legemidler inneholdende disse som den aktive bestanddel
ATE269305T1 (de) 1,4-disubstituierte piperidinderivate
WO2005021515A3 (en) Inhibitors of phosphodiesterase type-iv
CA2687625A1 (en) 3-(imidazolyl)-pyrazolo[3,4-b]pyridines
EP1640366A4 (en) HETEROCYCLES METHYLSULFON DERIVATIVE
AU6471200A (en) Substituted aromatic-ring compounds, process for producing the same, and use
WO2003068776A1 (fr) Derives de (1, 2, 4) triazolo (1,5-c) pyrimidine
EP1889827A4 (en) INTERMEDIATE PRODUCT IN THE PREPARATION OF A [2- (3,3,5,5-TETRAMETHYLCYCLOHEXYL) PHENYL] PIPERAZINE COMPOUND
EP1621540A4 (en) HETEROCYCLIC COMPOUNDS CONTAINING NITROGEN AND USE THEREOF

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050310

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1077297

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20070522

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20080611

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1077297

Country of ref document: HK